
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4363379/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. Journal of Hepatology, 2015, 63, 131-140.	3.7	538
2	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. Journal of Hepatology, 2018, 68, 526-549.	3.7	506
3	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of Hepatology, 2018, 69, 385-395.	3.7	330
4	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. Cell Metabolism, 2019, 29, 174-182.e5.	16.2	246
5	HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology, 2019, 156, 2313-2329.e7.	1.3	184
6	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. Journal of Gastroenterology, 2019, 54, 367-376.	5.1	156
7	Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. Journal of Gastroenterology, 2015, 50, 350-360.	5.1	144
8	CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut, 2018, 67, 1493-1504.	12.1	131
9	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 2018, 9, 4962.	12.8	111
10	Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers, 2018, 10, 447.	3.7	107
11	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell, 2018, 174, 1200-1215.e20.	28.9	96
12	The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 1272-1273.	3.7	79
13	Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus–Infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology, 2019, 157, 537-551.e9.	1.3	71
14	Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Journal of Hepatology, 2019, 70, 78-86.	3.7	71
15	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Scientific Reports, 2019, 9, 10663.	3.3	57
16	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut, 2021, 70, 157-169.	12.1	57
17	Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients WithÂSevere Alcoholic Hepatitis. Gastroenterology, 2018, 154, 965-975.	1.3	41
18	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Science Translational Medicine, 2022, 14, .	12.4	40

#	Article	IF	CITATIONS
19	Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. Journal of Clinical Investigation, 2022, 132, .	8.2	33
20	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	4.4	31
21	Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis. PLoS ONE, 2014, 9, e91822.	2.5	30
22	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. Journal of Gastroenterology, 2020, 55, 227-243.	5.1	29
23	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. Journal of Gastroenterology, 2021, 56, 261-273.	5.1	28
24	Family history is an independent risk factor for the progression of gastric atrophy among patients with <i>Helicobacter pylori</i> infection. United European Gastroenterology Journal, 2017, 5, 32-36.	3.8	25
25	Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. Journal of Gastroenterology, 2018, 53, 1261-1275.	5.1	25
26	Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e111662.	2.5	24
27	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nature Communications, 2021, 12, 5525.	12.8	21
28	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver International, 2020, 40, 2522-2534.	3.9	20
29	Impact of serum levels of interleukinâ€6 and adiponectin on allâ€cause, liverâ€related, and liverâ€unrelated mortality in chronic hepatitis <scp>C</scp> patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 379-388.	2.8	19
30	Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 921-928.	2.8	18
31	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	1.3	17
32	Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (United States), 2015, 94, e901.	1.0	16
33	Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer, 2021, 10, 309-319.	7.7	16
34	Changes in Risk of Immediate Adverse Reactions to Iodinated Contrast Media by Repeated Administrations in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e76018.	2.5	15
35	Comparison of improved prognosis between hepatitis B―and hepatitis C―elated hepatocellular carcinoma. Hepatology Research, 2015, 45, E99-E107.	3.4	15
36	Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis. American Journal of Surgical Pathology, 2020, 44, 1406-1412.	3.7	15

#	Article	IF	CITATIONS
37	Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatology Research, 2016, 46, 259-268.	3.4	13
38	Omicsâ€derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatology Research, 2020, 50, 817-830.	3.4	13
39	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 317-325.	3.3	12
40	Gene signatureâ€MELD score and alcohol relapse determine longâ€ŧerm prognosis of patients with severe alcoholic hepatitis. Liver International, 2020, 40, 565-570.	3.9	12
41	A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. Nature Communications, 2020, 11, 2707.	12.8	11
42	Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. European Journal of Gastroenterology and Hepatology, 2014, 26, 1039-1046.	1.6	10
43	Drastically Reduced Neoplastic Seeding Related to Radiofrequency Ablation for Hepatocellular Carcinoma. American Journal of Gastroenterology, 2014, 109, 774-776.	0.4	10
44	Slight elevation of highâ€sensitivity <scp>C</scp> â€reactive protein to predict recurrence and survival in patients with early stage hepatitis <scp>C</scp> â€related hepatocellular carcinoma. Hepatology Research, 2015, 45, 645-655.	3.4	10
45	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. Journal of Clinical Medicine, 2020, 9, 3843.	2.4	10
46	IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal. Case Reports in Gastroenterology, 2012, 6, 784-789.	0.6	9
47	Spontaneous clearance of serum hepatitis <scp>C</scp> virus <scp>RNA</scp> during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis <scp>C</scp> . Hepatology Research, 2014, 44, E32-7.	3.4	8
48	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. Experimental Hematology, 2019, 79, 16-25.e3.	0.4	8
49	Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma. Hepatology, 2019, 70, 2216-2217.	7.3	7
50	Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. Molecular and Translational Medicine, 2019, , 3-25.	0.4	6
51	A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis. Clinical Gastroenterology and Hepatology, 2022, 20, e1188-e1191.	4.4	6
52	Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Seminars in Liver Disease, 2019, 39, 153-162.	3.6	5
53	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE, 2018, 13, e0200943.	2.5	4
54	Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. Hepatology Research, 2019, 49, 453-461.	3.4	4

#	Article	IF	CITATIONS
55	DETECT: Development of Technologies for Early HCC Detection. Gastroenterology, 2022, 163, 21-27.	1.3	4
56	Improved prognosis of hepatitis Câ€related hepatocellular carcinoma in the era of directâ€acting antivirals. Hepatology Communications, 2022, 6, 2496-2512.	4.3	4
57	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight, 2022, 7, .	5.0	4
58	Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2022, 20, 651-657.	4.4	3
59	Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. Molecular and Translational Medicine, 2019, , 195-224.	0.4	3
60	Viral Exposure Signature Associated with Liver Cancer Risk. Trends in Molecular Medicine, 2020, 26, 711-713.	6.7	2
61	MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation. Frontiers in Genetics, 2019, 10, 830.	2.3	1
62	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. SSRN Electronic Journal, 0, , .	0.4	0
63	Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. Advances in Cancer Research, 2022, , .	5.0	Ο